about
Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycleMetabolic syndrome and carotid intima-media thickness in chronic obstructive pulmonary disease.Asthma programmes in diverse regions of the world: challenges, successes and lessons learnt.MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation.Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.The ARIA score of allergic rhinitis using mobile technology correlates with quality-of-life: The MASK study.Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project).What should be the appropriate minimal duration for patient examination and evaluation in pulmonary outpatient clinics?Integrated care pathways for airway diseases (AIRWAYS-ICPs).Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5).Does asthma control as assessed by the asthma control test reflect airway inflammation?CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report.Multiple nodular and patchy infiltrations in a 34-year-old male.Does high-frequency chest wall oscillation therapy have any impact on the infective exacerbations of chronic obstructive pulmonary disease? A randomized controlled single-blind study.AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation.Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study.Asthma phenotypes in Turkey: a multicenter cross-sectional study in adult asthmatics; PHENOTURK study.International European Respiratory Society/American Thoracic Society guidelines on severe asthma.Daily allergic multimorbidity in rhinitis using mobile technology: a novel concept of the MASK study.Varenicline disrupts prepulse inhibition only in high-inhibitory rats.Asthma control test via text messaging: could it be a tool for evaluating asthma control?Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSSDevelopment and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paperWhat we should learn from the London OlympicsCountry activities of Global Alliance against Chronic Respiratory Diseases (GARD): focus presentations at the 11th GARD General Meeting, Brussels2019 ARIA Care pathways for allergen immunotherapyMobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK studyMobile technology in allergic rhinitis: evolution in management or revolution in health and care?Relation between quality of life and morbidity and mortality in COPD patients: Two-year follow-up studyThe Global Alliance against Respiratory Diseases (GARD) Country Report[Treatment of severe asthma: expert opinion]Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1)ARIA 2019, Allerjik Rinite Tedavi Yaklaşımı-TürkiyeNext-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidenceNext-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2)Helsinki by nature: The Nature Step to Respiratory HealthPrioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic DiseasesGINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents
P50
Q26740215-E11C1FC3-A26B-4422-B409-2CCFE309A6A2Q28355722-E3B06D1D-1399-481B-A445-CC82E468F659Q37352193-067FB8ED-E01E-4DE9-9763-1F006966B0A9Q37925874-6CDDD9C9-854D-4ABA-B3AC-D0F466A97D3EQ38543189-3E5889AB-BEC4-4283-84E1-2C13505396CFQ38779963-FC43F8E4-48A6-42E5-9184-687E297ED612Q40041662-B8F9AE4A-CDDE-4D9E-AC2D-9A161E58D810Q40165178-4A36FE40-2329-4077-A012-25230D2EDF60Q41231249-D1E168A9-540C-4A4E-88B3-B46BE6207E89Q42210687-A2D5EA99-B65E-4DB9-978E-CAB27011FAE4Q42320566-3B80DA6C-42C0-451F-906A-552869AC0A20Q42532738-1B07D2CE-593D-4502-A1F1-B69270B915C0Q42643652-9C2C5409-51B8-4ADF-90DB-367A82D3971FQ43063877-0FA4AD06-EAFE-4061-AA1C-8701A1A069A6Q46735866-0B23840E-AD68-43B6-98C1-8F8BF1BEA863Q47444907-A57907C4-CA3E-4C72-9F5C-4F060E7290A0Q47559152-685F910A-6094-4098-9E45-2427A3A7FD8AQ51622159-03B9E4A9-DC04-482A-AA31-24104DC57A6EQ51686954-57505CA1-33EB-45D8-9790-278740EAE23BQ51760335-A3E5065F-E96B-4271-B629-07223A21623AQ52648542-C7997768-87BF-48A4-831D-69D48739B8ADQ56945718-30994B26-379A-40D0-93F4-2814FE703EF2Q56965360-BD1FDB6E-6296-494E-91E1-6AB6FBDF15DAQ57085035-8163B16D-E296-42FF-B9B6-5BD87193923EQ61684929-63FB2494-8039-463F-87BD-17D56D8B33DEQ62487152-49A88BE3-A6FE-4B0E-9EAE-27A46DCE72E3Q64447216-3AC17218-7211-44DC-9C5B-7597498314CEQ64447217-5F9C7B17-A865-4FD0-A928-758B246385A7Q66762163-4C08D88C-37C9-483B-BC39-F7A42E464228Q84621785-E2BD47BD-F6FE-4E3D-88D6-40B5D3558748Q87359807-C426FDB8-8CDC-4FC0-A039-3E928F868D1FQ87845467-20FA686A-4A5F-49AE-8895-7939145D4474Q90319583-A82441FC-3971-40BA-9F23-A20B343034AEQ90588707-C3348EE1-05A2-461F-B4D6-E5EA8FF1F088Q90807713-55119DCC-7652-4A21-823F-D6BF3C85E0C5Q90963533-A5EE3010-3627-48BE-9183-BDD483E2D33FQ91155077-94A2E56E-1627-4186-9C1C-19DB4BEF4A05Q91880645-5428B762-1A2B-4CA1-BA26-C2394249295FQ93087030-297A5EE4-EFB3-4C30-907C-F0B8A644256C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Arzu Yorgancioglu
@en
Arzu Yorgancioglu
@nl
type
label
Arzu Yorgancioglu
@en
Arzu Yorgancioglu
@nl
prefLabel
Arzu Yorgancioglu
@en
Arzu Yorgancioglu
@nl
P31
P496
0000-0002-4032-0944